Antiviral oligonucleotides
First Claim
1. An antiviral oligonucleotide formulation comprising at least one antiviral oligonucleotide, wherein the antiviral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.
1 Assignment
0 Petitions
Accused Products
Abstract
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.
117 Citations
40 Claims
- 1. An antiviral oligonucleotide formulation comprising at least one antiviral oligonucleotide, wherein the antiviral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.
-
2. An antiviral oligonucleotide formulation, comprising at least one antiviral randomer oligonucleotide, wherein the antiviral activity of said formulation occurs principally by a non-sequence complementary mode of action.
-
3. An oligonucleotide formulation having antiviral activity against a target virus, comprising at least one antiviral oligonucleotide, wherein said oligonucleotide is at least 29 nucleotides in length and the sequence of said oligonucleotide is not complementary to any portion of the genomic sequence of said target virus.
-
4. An oligonucleotide formulation having antiviral activity against a target virus, comprising at least one antiviral oligonucleotide, wherein said oligonucleotide is at least 6 nucleotides in length and the sequence of said oligonucleotide is not complementary to a mRNA of said target virus and does not consist essentially of polyA, polyc, polyG, polyT, Gquartet, or a TG-rich sequence.
-
27. A method for selecting an antiviral oligonucleotide for use as an antiviral agent, comprising
synthesizing a plurality of different random oligonucleotides; -
testing said oligonucleotides for activity in inhibiting the ability of a virus to produce infectious virions; and
selecting a said oligonucleotide having a pharmaceutically acceptable level of activity for use as an antiviral agent.
-
-
32. A method of screening to identify a compound that alters binding of an oligonucleotide to at least one viral component, said method comprising
in separate reactions, contacting said oligonucleotide with said viral component in the presence and absence of a compound to be screened; - and
determining whether a difference occurs in binding of said oligonucleotide to said viral component in the presence of said compound compared to in the absence of said compound, the presence of said difference being indicative of said compound altering the binding of said oligonucleotide to said viral component. - View Dependent Claims (33)
- and
-
34. A method for purifying oligonucleotides binding to at least one viral component from a pool of oligonucleotides comprising:
-
contacting said pool with at least one viral component;
displacing bound oligonucleotides of said pool from said viral component; and
collecting displaced oligonucleotides. - View Dependent Claims (35, 39, 40)
-
-
36. A method for enriching oligonucleotides from a pool of oligonucleotides binding to at least one viral component, comprising:
-
contacting said pool with at least one viral component; and
amplifying oligonucleotides bound to said viral component to provide an enriched oligonucleotide pool. - View Dependent Claims (37, 38)
-
Specification